Industry Briefs: November 12, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: November 12, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AstraZeneca and Foundation Medicine have entered into a collaboration to identify alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines. Read More

Boehringer Ingelheim and BaroFold have entered into a nonexclusive technology and commercial license option agreement. Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold’s pressure-enabled manufacturing technology that can also be qualified for GMP use. The technology will be installed at Boehringer Ingelheim’s microbial facility in Vienna, Austria, and will be available for development of biopharmaceutical production processes. Read More

Cytovance Biologics and Selexys Pharmaceuticals have formed a biomanufacturing agreement for Phase II Production of the monoclonal antibody SelG1. Read More

GP Pharm has agreed to manufacture Pharmalink’s Busulipo, which is under development to provide a conditioning agent for use before hematopoietic stem-cell transplantation, or bone-marrow transplantation. Read More

Immune Pharmaceuticals and EpiCept have entered into a definitive merger agreement. The transaction is expected to close during the first quarter of 2013. Read More

Merck & Co. and the Regenstrief Institute have signed a five-year agreement to collaborate on a range of projects that will use clinical data to inform personalized delivery of healthcare. Read More

MonoSol Rx and BiondVax Pharmaceuticals have entered an agreement to develop oral delivery for BiondVax’s universal flu vaccine, M-001. Read More

Mylan and Famy Care have entered into a settlement agreement with Janssen Pharmaceuticals that will resolve patent litigation related to norgestimate/ethinyl estradiol tablets 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg. Norgestimate/ethinyl estradiol tablets are the generic version of Janssen’s Ortho Tri-Cyclen Lo Tablets, which are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Read More

Pfizer has concluded its partnership with Auxilium Pharmaceuticals for Xiapex (collagenase clostridium histolyticum) in the European Union. Read More

Sigma-Aldrich has acquired Research Organics. Read More

Synthetic Biologics has agreed to acquire Prev AbR’s clinical-stage C. difficile infectious-disease program. Read More

People News

Bosch Packaging Technology has announced several leadership changes. Uwe Harbauer has been appointed senior vice-president of the company’s pharmaceutical business unit, Wolfgang Szczerba is retiring after 34 years of service at Bosch, and Walter Häcki has been appointed senior vice-president of packaging services. Read More

Tyson Popp, vice-president, global sourcing and Americas supply chain, West Pharmaceutical Services, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT) by the DCAT membership. He assumed the office on Nov. 1, 2012. Also elected to serve as officers were Lyra Myers, associate director and value creation agent, Genentech; George Svokos, senior vice president, product and portfolio management, Teva Pharmaceuticals USA; and Folker Ruchatz, vice-president, global business management custom synthesis, BASF. Read More

Novartis has announced that Marjorie Yang has decided not to seek re-election to the Novartis board of directors. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here